# OnCo record ibrutinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ibrutinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ibrutinib" ;
  schema:name "Ibrutinib"@en ;
  schema:description "The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting."@en ;
  schema:url <https://onco.cc/drugs/ibrutinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ibrutinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5984881> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ibrutinib>, <https://doi.org/10.1016/j.annonc.2021.01.070>, <https://doi.org/10.1038/nature08638>, <https://doi.org/10.1056/NEJMoa1400029> ;
  onco:status "approved" ;
  onco:modality "Small-molecule covalent BTK inhibitor (first generation)" ;
  schema:alternateName "Imbruvica" ;
  onco:approval "US 2013: Relapsed mantle cell lymphoma (accelerated); first BTK inhibitor", "US 2014: Relapsed CLL (RESONATE); del(17p) CLL", "US 2016: First-line CLL (RESONATE-2)", "EU 2014: Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation", "EU 2022: Fixed-duration ibrutinib + venetoclax, first-line CLL (GLOW, CAPTIVATE)" ;
  onco:acceleratedApproval "US 2013-11-13: Adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy", "US 2014-02-12: Chronic lymphocytic leukemia after at least one prior therapy", "US 2017-01-18: Adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy" ;
  onco:acceleratedApprovalConfirmed "US 2014-07-28: Chronic lymphocytic leukemia after at least one prior therapy" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/resonate/>, <https://onco.cc/trials/captivate/>, <https://onco.cc/trials/glow/>, <https://onco.cc/trials/alpine/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct03960840/>, <https://onco.cc/trials/nct05283720/>, <https://onco.cc/trials/nct03379428/>, <https://onco.cc/trials/nct02477696/>, <https://onco.cc/trials/nct04509700/>, <https://onco.cc/trials/nct05254743/>, <https://onco.cc/trials/nct05963074/>, <https://onco.cc/trials/nct04494503/>, <https://onco.cc/trials/nct04662255/>, <https://onco.cc/trials/resolve/> .